This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second View: Discussing the Losmapimod data for Facioscapulohumeral muscular dystrophy (FSHD) from Fulcrum Therapeutics

Ticker(s): FULC

Who's the expert?

Institution: University of Buffalo

  • Clinical Associate Professor of Neurology at the University of Buffalo.
  • Research is focused on several studies that address illnesses such as Guillain-Barre syndrome, myasthenia gravis and polyneuropathy.
  • Basic science research is focused on pathophysiology of inherited neuropathies, which are known collectively as Charcot-Marie-Tooth (CMT) disease, with the goal of better understanding the underlying cause or mechanisms of these diseases.

Interview Questions
Q1.

How many FSHD patients do you treat?

Added By: wilson_admin
Q2.

What are your opinions of the phase 2 data?

Added By: wilson_admin
Q3.

What do you think about the phase 3 trial design?

Added By: wilson_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.